Novartis AG ADR
I · Analyse IA
En bref
Novartis develops and sells prescription medicines across cardiovascular disease (Entresto for heart failure), immunology (Cosentyx for psoriasis and arthritis), oncology (Pluvicto for prostate cancer, Kisqali for breast cancer), and rare diseases (Zolgensma for spinal muscular atrophy) [Yahoo Finance]. The company operates globally, manufacturing drugs in multiple countries and selling through hospitals, clinics, and specialty pharmacies [Yahoo Finance].
Novartis is a Swiss pharmaceutical giant with over 75,000 employees making drugs for heart disease, cancer, immune disorders, and rare genetic conditions [Yahoo Finance]. The company posted $54.8B in revenue with strong margins (75% gross, 32% operating) and solid cash generation ($17.7B free cash flow), reflecting a diversified portfolio of branded medicines [Yahoo Finance]. Recent positive clinical trial results for Pluvicto, a radioactive cancer therapy, have driven modest stock gains and positioned Novartis as a leader in an emerging treatment category [Simply Wall St].
Novartis is financially healthy with strong profitability, low leverage, and consistent cash generation [Yahoo Finance].
Score Sentinellis
8.9/10
Financially healthy
Capitalisation boursière
$287.1B
Chiffre d'affaires (12 mois)
$54.8B
II · Actualités récentes
Ce qui a fait bouger le cours
6 stories · ranked by relevance
- macro2026-05-20
Novartis (SWX:NOVN) Valuation Check After New Pluvicto PSMAddition Study Data And Regulatory Filings
Simply Wall St
- macro2026-05-18
Hepatic Cirrhosis Market Research and Forecast Report 2026-2036, Profiles of Abbott, Astellas Pharma, Gilead Sciences, Novartis, Takeda Pharma, Grifols Therapeutics, and Cellaion
Yahoo Finance
- macro2026-05-18
Novartis' Pluvicto Shows Lower Risk Of PSA Progression In Phase 3 PSMAddition Trial For MHSPC
Nasdaq
- macro2026-05-14
Novartis Expands US Radioligand Network And Manufacturing For Future Growth
Simply Wall St
- macro2026-05-17
New PSMAddition data show 58% lower risk of PSA progression with Pluvicto® in metastatic hormone-sensitive prostate cancer
Yahoo Finance
- macro2026-05-14
Interleukin-6 (IL-6) Receptor Antagonists and IL6- Inhibitors Pipeline Competitor Analysis Report 2026: Active R&D Programs by R&D Phase and Profile of Antagonists and Inhibitors by Drug Modality
Yahoo Finance
Premium · gratuit avec tout compte
Patent expirations on blockbuster drugs will eventually erode revenue unless the pipeline delivers replacements — a structural risk in pharmaceutical business models [Yahoo Finance]
Risques
4
Opportunités
5
Signaux d'alerte
2
Direction
10
20 autres constats dans le rapport complet — gratuit avec tout compte.
Débloquer l'analyse complète de Novartis AG ADR
Créez un compte gratuit pour accéder au rapport complet généré par IA, avec les sources citées dans le texte.
- 4 risques, 5 opportunités et 2 signaux d'alerte — chacun avec sa source
- Plus de 100 indicateurs financiers avec graphiques et comparaisons
- Résumés d'actualités complets avec liens vers les sources
- Équipe dirigeante et rémunération
- Export PDF pour la lecture hors ligne
III · Entreprises similaires
À lire également
Same sector · Healthcare or comparable health
L'ajouter à votre liste ?